Cargando…

In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways

Lactic acid bacteria, including the microorganisms formerly designated as Lactobacillus, are the major representatives of Live Biotherapeutic Microorganisms (LBM) when used for therapeutic purposes. However, in most cases, the mechanisms of action remain unknown. The antifungal potential of LBM has...

Descripción completa

Detalles Bibliográficos
Autores principales: Poupet, Cyril, Rifa, Étienne, Theil, Sébastien, Bonnet, Muriel, Veisseire, Philippe, Cardin, Guillaume, Guéret, Élise, Rialle, Stéphanie, Chassard, Christophe, Nivoliez, Adrien, Bornes, Stéphanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816150/
https://www.ncbi.nlm.nih.gov/pubmed/36620055
http://dx.doi.org/10.3389/fmicb.2022.1062113
_version_ 1784864467424641024
author Poupet, Cyril
Rifa, Étienne
Theil, Sébastien
Bonnet, Muriel
Veisseire, Philippe
Cardin, Guillaume
Guéret, Élise
Rialle, Stéphanie
Chassard, Christophe
Nivoliez, Adrien
Bornes, Stéphanie
author_facet Poupet, Cyril
Rifa, Étienne
Theil, Sébastien
Bonnet, Muriel
Veisseire, Philippe
Cardin, Guillaume
Guéret, Élise
Rialle, Stéphanie
Chassard, Christophe
Nivoliez, Adrien
Bornes, Stéphanie
author_sort Poupet, Cyril
collection PubMed
description Lactic acid bacteria, including the microorganisms formerly designated as Lactobacillus, are the major representatives of Live Biotherapeutic Microorganisms (LBM) when used for therapeutic purposes. However, in most cases, the mechanisms of action remain unknown. The antifungal potential of LBM has already been demonstrated using preclinical models (cell cultures, laboratory animals). Understanding their mechanisms of action is strategic for the development of new therapeutics for humans. Here, Caenorhabditis elegans was used as an in vivo model to analyze pro-longevity, anti-aging and anti-candidiasis effects of the LBM Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus) Lcr35(®). A high-throughput transcriptomic analysis revealed a specific response of C. elegans depending on whether it is in the presence of the LBM L. rhamnosus Lcr35(®) (structural response), the yeast Candida albicans (metabolic response) or both (structural and metabolic responses) in a preventive and a curative conditions. Studies on C. elegans mutants demonstrated that the p38 MAPK (sek-1, skn-1) and the insulin-like (daf-2, daf-16) signaling pathways were involved in the extended lifespan provided by L. rhamnosus Lcr35(®) strain whereas the JNK pathway was not involved (jnk-1). In addition, the anti C. albicans effect of the bacterium requires the daf-16 and sek-1 genes while it is independent of daf-2 and skn-1. Moreover, the anti-aging effect of Lcr35(®), linked to the extension of longevity, is not due to protection against oxidative stress (H(2)O(2)). Taken together, these results formally show the involvement of the p38 MAP kinase and insulin-like signaling pathways for the longevity extension and anti-Candida albicans properties of Lcr35(®) with, however, differences in the genes involved. Overall, these findings provide new insight for understanding the mechanisms of action of a probiotic strain with antimicrobial potential.
format Online
Article
Text
id pubmed-9816150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98161502023-01-07 In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways Poupet, Cyril Rifa, Étienne Theil, Sébastien Bonnet, Muriel Veisseire, Philippe Cardin, Guillaume Guéret, Élise Rialle, Stéphanie Chassard, Christophe Nivoliez, Adrien Bornes, Stéphanie Front Microbiol Microbiology Lactic acid bacteria, including the microorganisms formerly designated as Lactobacillus, are the major representatives of Live Biotherapeutic Microorganisms (LBM) when used for therapeutic purposes. However, in most cases, the mechanisms of action remain unknown. The antifungal potential of LBM has already been demonstrated using preclinical models (cell cultures, laboratory animals). Understanding their mechanisms of action is strategic for the development of new therapeutics for humans. Here, Caenorhabditis elegans was used as an in vivo model to analyze pro-longevity, anti-aging and anti-candidiasis effects of the LBM Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus) Lcr35(®). A high-throughput transcriptomic analysis revealed a specific response of C. elegans depending on whether it is in the presence of the LBM L. rhamnosus Lcr35(®) (structural response), the yeast Candida albicans (metabolic response) or both (structural and metabolic responses) in a preventive and a curative conditions. Studies on C. elegans mutants demonstrated that the p38 MAPK (sek-1, skn-1) and the insulin-like (daf-2, daf-16) signaling pathways were involved in the extended lifespan provided by L. rhamnosus Lcr35(®) strain whereas the JNK pathway was not involved (jnk-1). In addition, the anti C. albicans effect of the bacterium requires the daf-16 and sek-1 genes while it is independent of daf-2 and skn-1. Moreover, the anti-aging effect of Lcr35(®), linked to the extension of longevity, is not due to protection against oxidative stress (H(2)O(2)). Taken together, these results formally show the involvement of the p38 MAP kinase and insulin-like signaling pathways for the longevity extension and anti-Candida albicans properties of Lcr35(®) with, however, differences in the genes involved. Overall, these findings provide new insight for understanding the mechanisms of action of a probiotic strain with antimicrobial potential. Frontiers Media S.A. 2022-12-23 /pmc/articles/PMC9816150/ /pubmed/36620055 http://dx.doi.org/10.3389/fmicb.2022.1062113 Text en Copyright © 2022 Poupet, Rifa, Theil, Bonnet, Veisseire, Cardin, Guéret, Rialle, Chassard, Nivoliez and Bornes. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Poupet, Cyril
Rifa, Étienne
Theil, Sébastien
Bonnet, Muriel
Veisseire, Philippe
Cardin, Guillaume
Guéret, Élise
Rialle, Stéphanie
Chassard, Christophe
Nivoliez, Adrien
Bornes, Stéphanie
In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title_full In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title_fullStr In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title_full_unstemmed In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title_short In vivo investigation of Lcr35(®) anti-candidiasis properties in Caenorhabditis elegans reveals the involvement of highly conserved immune pathways
title_sort in vivo investigation of lcr35(®) anti-candidiasis properties in caenorhabditis elegans reveals the involvement of highly conserved immune pathways
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816150/
https://www.ncbi.nlm.nih.gov/pubmed/36620055
http://dx.doi.org/10.3389/fmicb.2022.1062113
work_keys_str_mv AT poupetcyril invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT rifaetienne invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT theilsebastien invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT bonnetmuriel invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT veisseirephilippe invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT cardinguillaume invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT gueretelise invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT riallestephanie invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT chassardchristophe invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT nivoliezadrien invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways
AT bornesstephanie invivoinvestigationoflcr35anticandidiasispropertiesincaenorhabditiselegansrevealstheinvolvementofhighlyconservedimmunepathways